Advertisement

Serum cartilage oligomeric matrix protein levels as a novel non-invasive biomarker for liver fibrosis in patients with chronic viral hepatitis? It is too early

  • Rui Huang
    Affiliations
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
    Search for articles by this author
  • Juan Xia
    Affiliations
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
    Search for articles by this author
  • Xiaomin Yan
    Affiliations
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
    Search for articles by this author
  • Yong Liu
    Affiliations
    Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
    Search for articles by this author
  • Chao Wu
    Correspondence
    Corresponding author at: Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, Jiangsu, China.
    Affiliations
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
    Search for articles by this author
Published:April 18, 2017DOI:https://doi.org/10.1016/j.ejim.2017.04.009
      We read with great interest the recently published article by Zachou et al., in which they investigated the possible application of serum cartilage oligomeric matrix protein (COMP) levels as a novel non-invasive marker of fibrosis in patients with chronic viral hepatitis (CVH) and compared this marker with histology, transient elastography (TE), APRI and FIB-4 for the estimation of fibrosis stage [
      • Zachou K.
      • Gabeta S.
      • Shums Z.
      • et al.
      COMP serum levels: a new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis.
      ]. They concluded that serum COMP levels performed as well as TE, APRI and FIB-4 score in detecting cirrhosis in CVH patients [
      • Zachou K.
      • Gabeta S.
      • Shums Z.
      • et al.
      COMP serum levels: a new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis.
      ]. It is a nice work. However, we are concerned about several points in this article.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zachou K.
        • Gabeta S.
        • Shums Z.
        • et al.
        COMP serum levels: a new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis.
        Eur J Intern Med. 2017; 38: 83-88https://doi.org/10.1016/j.ejim.2017.01.007
        • Xiao Y.
        • Kleeff J.
        • Guo J.
        • et al.
        Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver.
        J Gastroenterol Hepatol. 2004; 19: 296-302
      1. Norman GL, Gatselis NK, Shums Z, et al. Cartilage oligomeric matrix protein: a novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol 2015;7:1875–83. http://dx.doi.org/10.4254/wjh.v7.i14.1875.

        • Sarin S.K.
        • Kumar M.
        • Lau G.K.
        • et al.
        Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
        Hepatol Int. 2016; 10: 1-98https://doi.org/10.1007/s12072-015-9675-4
      2. Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int 2017;11(1):1–30. doi: 10.1007/s12072-016-9760-3.

        • WHO Guidelines Approved by the Guidelines Review Committee
        Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.
        World Health Organization, Geneva2015